Hualan Biological Engineering Inc
SZSE:002007
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.84
24.44
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hualan Biological Engineering Inc
Cash from Financing Activities
Hualan Biological Engineering Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Hualan Biological Engineering Inc
SZSE:002007
|
Cash from Financing Activities
-ÂĄ483.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-11%
|
||
Beigene Ltd
HKEX:6160
|
Cash from Financing Activities
ÂĄ2.6B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Cash from Financing Activities
ÂĄ960.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Financing Activities
-ÂĄ893.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash from Financing Activities
-ÂĄ1.2B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Financing Activities
-ÂĄ2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-39%
|
Hualan Biological Engineering Inc
Glance View
Hualan Biological Engineering, Inc. engages in the research and development, production, and sale of biological products. The company is headquartered in Xinxiang, Henan and currently employs 2,927 full-time employees. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.
See Also
What is Hualan Biological Engineering Inc's Cash from Financing Activities?
Cash from Financing Activities
-483.6m
CNY
Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Cash from Financing Activities amounts to -483.6m CNY.
What is Hualan Biological Engineering Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-11%
Over the last year, the Cash from Financing Activities growth was 5%.